Header

UZH-Logo

Maintenance Infos

New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses


Jonsdottir, Sigridur; Cvitas, Iva; Svansson, Vilhjalmur; Fettelschloss-Gabriel, Antonia; Torsteinsdottir, Sigurbjorg; Marti, Eliane (2019). New Strategies for Prevention and Treatment of Insect Bite Hypersensitivity in Horses. Current Dermatology Reports, 8:303-312.

Abstract

Purpose of Review
Treatment of equine insect bite hypersensitivity (IBH) needs to be improved. Allergen-specific immunotherapy (ASIT), the only curative treatment of allergy, currently has only a limited efficacy for treatment of IBH. This review highlights the latest findings in prophylactic and therapeutic strategies.
Recent Findings
Prophylactic vaccination against IBH using recombinant Culicoides allergen has been developed in unexposed Icelandic horses and is ready to be tested. Therapeutic virus-like particle (VLP)–based vaccines targeting equine interleukin- (IL-) 5 or IL-31 improved clinical signs of IBH by induction of anti-cytokine antibodies thus reducing eosinophil counts or allergic pruritus, respectively.
Summary
First studies for development of ASIT using pure r-Culicoides allergens have yielded promising results and need now to be tested in clinical studies for both prevention and treatment of IBH. Therapeutic vaccines inducing neutralizing antibodies against IL-5 or IL-31 will be valuable future treatments for reduction of clinical signs of IBH.

Abstract

Purpose of Review
Treatment of equine insect bite hypersensitivity (IBH) needs to be improved. Allergen-specific immunotherapy (ASIT), the only curative treatment of allergy, currently has only a limited efficacy for treatment of IBH. This review highlights the latest findings in prophylactic and therapeutic strategies.
Recent Findings
Prophylactic vaccination against IBH using recombinant Culicoides allergen has been developed in unexposed Icelandic horses and is ready to be tested. Therapeutic virus-like particle (VLP)–based vaccines targeting equine interleukin- (IL-) 5 or IL-31 improved clinical signs of IBH by induction of anti-cytokine antibodies thus reducing eosinophil counts or allergic pruritus, respectively.
Summary
First studies for development of ASIT using pure r-Culicoides allergens have yielded promising results and need now to be tested in clinical studies for both prevention and treatment of IBH. Therapeutic vaccines inducing neutralizing antibodies against IL-5 or IL-31 will be valuable future treatments for reduction of clinical signs of IBH.

Statistics

Citations

Dimensions.ai Metrics
14 citations in Web of Science®
15 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

59 downloads since deposited on 23 Jun 2020
11 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Dermatology
Language:English
Date:1 December 2019
Deposited On:23 Jun 2020 11:58
Last Modified:23 Jul 2024 01:39
Publisher:Springer
ISSN:2162-4933
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1007/s13671-019-00279-w
  • Content: Published Version
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)